Latest stories on CVKD
Cadrenal Therapeutics Begins Strategic Review of Orphan Portfolio
TipRanks55 · neutralgeneral
Cadrenal Therapeutics, Inc. (CVKD) files 8-K
SEC 8-K50 · neutralgeneral
Cadrenal Therapeutics initiates process to evaluate opportunities
The Fly55 · neutralgeneral
Cadrenal Therapeutics, Inc. (CVKD) files 8-K
SEC 8-K50 · neutralgeneral
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
Business Insider55 · neutralgeneral
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
GlobeNewswire55 · neutralgeneral
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Business Insider55 · neutralgeneral
Cadrenal Therapeutics advances CAD-1005 Phase 3 pathway
TipRanks67 · bullishproduct/pr
Cadrenal Therapeutics, Inc. (CVKD) files 8-K
SEC 8-K50 · neutralgeneral
Cadrenal Therapeutics gets feedback from CAD-1005 Type D Meeting with FDA
The Fly59 · neutralgeneral
Cadrenal Therapeutics, Inc. (CVKD) files 8-K
SEC 8-K50 · neutralgeneral
Cadrenal Therapeutics Launches Cardiac Acute Care Franchise Strategy
TipRanks56 · neutralproduct/pr
Cadrenal Therapeutics, Inc. (CVKD) files 8-K
SEC 8-K50 · neutralgeneral
Cadrenal Therapeutics Announces Chief Medical Officer Transition
TipRanks50 · neutralgeneral
Cadrenal Therapeutics, Inc. (CVKD) files 8-K
SEC 8-K50 · neutralgeneral
Cadrenal Therapeutics, Inc. (CVKD) files 8-K
SEC 8-K50 · neutralgeneral
Cadrenal Therapeutics Secures Private Placement to Extend Runway
TipRanks34 · bearishgeneral